Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received expanded indication approval from...
NYSE: NVS
Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
Swiss pharmaceutical giant Novartis’ (NYSE: NVS) iptacopan, marketed as Fabhalta, has received approval from the...
Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa
Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National...
Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development
Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...
Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...
Novartis to Defend Entresto Patent After CAFC Ruling
Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for...
Novartis Announces Positive Results from Phase III STEER Study on SMA Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive topline results from the Phase III...
BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets
US-based BioAge Labs, Inc. has announced a strategic research partnership with Swiss pharmaceutical giant Novartis...
UCB’s Minzasolmin Fails to Meet Endpoints in ORCHESTRA Study for Early Parkinson’s
Belgium-based biopharmaceutical company UCB (EBR: UCB) has announced the disappointing results of the ORCHESTRA proof-of-concept...
Siemens Healthineers AG Acquires Advanced Accelerator Applications to Boost PETNET Solutions
Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced...
Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024
Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...
Novartis’ Fabhalta Demonstrates Positive Results in APPULSE-PNH Phase IIIb Study
Swiss pharmaceutical major Novartis (NYSE: NVS) has released positive topline results from the APPULSE-PNH Phase...
Tasly Pharma Receives NMPA Approval for Generic Lioresal (Baclofen) Oral Solution
China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received marketing approval...
Novartis Secures Global Rights to PTC Therapeutics’ Huntington’s Disease Treatment PTC518
Swiss pharmaceutical giant Novartis (NYSE: NVS) has entered into a global license and collaboration agreement...
Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced that it has received marketing approval from...
Novartis Expands Gene Therapy Portfolio with Acquisition of Kate Therapeutics
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced the acquisition of US-based Kate Therapeutics, Inc.,...
Ratio Therapeutics Partners with Novartis on SSTR2 Radiotherapeutic for Cancer
US-based Ratio Therapeutics Inc. has entered into a global exclusive licensing and cooperation agreement with...
Novartis’ Pluvicto Accepted for Review by China’s NMPA for Prostate Cancer Treatment
The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has accepted...
Schrödinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates
New York-based Schrödinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has...